Fluence Supporting Premium Dutch Floriculture Brands to Future-Proof and Increase Sustainability
9.2.2023 16:30:00 EET | Business Wire | Press release
Fluence, a leading global provider of energy-efficient LED lighting solutions for floriculture, medicinal cannabis and food production, is supporting sustainability and operational cost efficiency amid volatile energy market conditions in Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230209005211/en/
Orchids under Fluence LED lighting at Bernhard Kwekerijen, a rose, orchid and patio plant nursery. (Photo: Business Wire)
Europe’s soaring energy prices have affected many growers in countries like the Netherlands that primarily produce electricity via the gas-powered cogeneration method. Gas prices have historically balanced between €15 and €20 per megawatt-hour (MWh) but peaked at over €300 per MWh in 2022 because of volatility due to supply, storage and weather conditions. Current energy prices have dropped to €60 per MWh, remaining roughly three times higher than what many growers planned to pay for electricity.
Leading floriculture companies dedicated to delivering high-quality products to customers—including Bernhard Kwekerijen, Moerman Lilium, Deliflor Chrysanten, Beyond Chrysant and Ten Have Plant—have made the switch from high-pressure sodium (HPS) fixtures to Fluence's LED technology, which increase photon output and energy efficiency.
“As they confront the unpredictability of Europe’s energy market, Dutch cultivators are increasingly focused on future-proofing their cultivation strategies by decreasing their dependency on fossil energy and engaging in sustainable practices,” said Gert-Jan Goes, horticulture specialist at Fluence. “Fluence’s RAPTR light fixture and Wireless Flex Dimming control panel help growers maximize their return on investment while increasing control over light intensity while increasing control over light intensity and dimming up and down creates maximum flexibility to profit from highly fluctuating energy markets.”
Moerman Lilium, a lily cultivator, has 13 hectares of crops under full LED lighting and uses Fluence’s RAPTR fixtures regulated via a Wireless Flex Dimming controller. The company—which monitors European energy prices very closely—uses Fluence solutions to react quickly and modify light intensity based on market conditions. Moerman Lilium expects to save at least 45% on electricity costs with the investment in Fluence’s LED lighting solutions.
“LED lighting allows us to be more energy efficient while adjusting our electricity use based on fluctuations in energy prices,” said Jan Moerman, co-owner of Moerman Lilium. “Switching to Fluence LEDs has saved us money and given us more flexibility in a constantly changing energy market.”
Deliflor Chrysanten is the global market leader in breeding and propagating chrysanthemum varieties. The company was in search of a high-efficiency lighting solution featuring additional green light in the spectrum for better visibility and growth. Deliflor Chrysanten opted for Fluence’s RAPTR Broad R8 spectrum in their recently renewed breeding facilities to guarantee the best circumstances for their newest varieties. The first flower trial grown under the Fluence’s fixtures turned out very successful last January. Beyond Chrysant, a leading Dutch chrysanthemum cultivator, also chose Fluence’s RAPTR solution for its customizability and high-visibility spectrum that create increased efficiency in its integrated crop management practices. Installing Fluence’s LED technology has allowed Beyond Chrysant to gain greater control over the oscillating European energy market. The company was recently named a finalist for Stichting Tuinbouw Ondernemersprijs’ “2023 Horticultural Entrepreneur Award.”
Even in hybrid lighting environments, growers are seeing the benefits of using LED technology. Bernhard Kwekerijen—a rose, orchid and patio plant nursery—promotes a carbon-neutral and sustainable operation by using geothermal heat and its own photovoltaic field of solar panels to generate energy. By incorporating Fluence’s RAPTR fixtures alongside legacy HPS solutions and maximizing light control with Wireless Flex Dimming, Bernhard Kwekerijen has elevated CO2-neutral cropping in its Phalaenopsis cultivation.
“Fluence’s technology stands out because it affords the greatest flexibility in modifying energy consumption and light intensity according to energy market price instability,” said Dennis Raadschelders, strategic account manager for commercial agriculture at Fluence. “Our Dutch floriculture growers have harnessed control over operational expenses without sacrificing product quality by emitting more light when energy prices are low, and quickly reducing light when energy prices rise.”
Fluence’s team of horticultural experts work closely alongside partners to design lighting programs based on operations-specific crop and sustainability goals. Ten Have Plant, one of the oldest potted plant nurseries in Westland, selected Fluence as its lighting solutions partner to achieve better crop and root development in addition to reducing costs and increasing energy efficiency. Ten Have Plant worked with Fluence’s horticulture team to design a lighting plan to produce cyclamen for half the year and campanula in the other half, selecting VYPR 3p Broad R6 top lights to gain control over seasonal light conditions and electricity consumption year-round.
“Fluence LED fixtures are widely used by leading cannabis, commercial agriculture and floriculture companies across Europe, demonstrating the flexibility and universal benefit in transitioning to LED technology,” said David Cohen, CEO of Fluence. “We are excited to work with Dutch floriculture growers who have deep roots in the industry and support their management of environmental conditions, sustainable operations and the highest quality crops.”
For more information on Fluence, visit www.fluence.science.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230209005211/en/
Contact information
For EMEA,
Silvia Nagyova
silvia.nagyova@fluence-led.com
+49 160 93335045
For North America,
Callie Neatherlin
callie@redfancommunications.com
512-439-9720
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
